Beverly G. Tchang, MD
@bevtchangmd
#Endocrinologist. Passionate about #obesity as a medical disease and a social misunderstanding. Tweets are my own. | #health #medtwitter #weightloss #medicine |
ID: 874601238062657536
https://www.beverlytchangmd.com/ 13-06-2017 12:15:59
5,5K Tweet
5,5K Followers
2,2K Following
There's no scientific backing to needing to eat 3 meals a day. I'm not even sure if there's evidence for one meal everyday. Help? Nina Crowley PhD RDN Michelle Cardel, PhD, MS, RD
If you're following the alphabet soup of gut peptides, pay attention to FGF21 Nice review from Endocrine Society on how FGF21 mediates sex-specific handling of lipid and protein catabolism 🐁 academic.oup.com/jcem/article/1… 👉FGF21: ⬆️ lipid oxidation in ♂ but ⬆️ lipid storage in ♀
#HellthInsurance How UnitedHealthcare destroyed a primary care network in CT statnews.com/2024/08/28/uni…
You don't often see Kevin Hall & Dr. David Ludwig on the same paper so when I do, you better believe it's #1 on the reading list. nature.com/articles/s4225… Very thorough synthesis of CIM and EBM. One piece I disagree with is the false dichotomy re: management. Do both. #obesity
Hims, one of the biggest faces of compounded GLP-1s online, has doubled down by saying it will continue compounding the drugs even when shortages end. What comes next? Nicholas Florko and I looked at the web of regulations it will have to deal with: statnews.com/2024/08/29/tel…
I plan to attend this #webinar: us02web.zoom.us/webinar/regist… The funded by PepsiCo makes me bristle But Andrew W Brown being a speaker gives me hope #Science communication is crucial to education and right now, the hacks are winning :/ #nutrition #research
Every branded Semaglutide and Tirzepatide pen should be Multi-use. These single-use pens are wasteful and an environmental hazard. Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 On The Pen Beverly G. Tchang, MD #ReleaseMultiusePens #GreenerHealthcare #StopMedicalWaste #ReuseYourPen #EcoFriendlyPharma
#Hellthcare episode 263 UnitedHealthcare now requiring prior authorization for every dose increase for tirzepatide even when the plan sets quantity limited for the dose already approved (7.5)
How do leading obesity drugs compare?💉 My latest news story for nature explores the differences between medications like semaglutide and tirzepatide. With insights from Daniel J Drucker, Beverly G. Tchang, MD, and Christian Hölscher. nature.com/articles/d4158…
Thanks Mariana Lenharo for highlighting our latest thoughts and questions on the godzilla v king kong battle of #GLP1s nature.com/articles/d4158… @nature #obesity #weightmanagement #diabetes
Looking forward to this #free #webinar on medical and surgical management of #obesity led by two of my esteemed colleagues Dr Gregory Dakin and Dr Sarah Barenbaum Weill Cornell Medicine Sept 23 6:30PM ET 👉nyph.zoom.us/webinar/regist…